Acumen Pharmaceuticals Stock Net Asset
| ABOS Stock | USD 1.38 0.08 5.48% |
Fundamental analysis of Acumen Pharmaceuticals allows traders to better anticipate movements in Acumen Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
Acumen | Net Asset | Build AI portfolio with Acumen Stock |
Acumen Pharmaceuticals Company Net Asset Analysis
Acumen Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Acumen Pharmaceuticals Net Asset | 238.99 M |
Most of Acumen Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acumen Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Acumen Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Acumen Pharmaceuticals is extremely important. It helps to project a fair market value of Acumen Stock properly, considering its historical fundamentals such as Net Asset. Since Acumen Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acumen Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acumen Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Acumen Total Assets
Total Assets |
|
Based on the recorded statements, Acumen Pharmaceuticals has a Net Asset of 238.99 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Acumen Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acumen Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acumen Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acumen Pharmaceuticals by comparing valuation metrics of similar companies.Acumen Pharmaceuticals is currently under evaluation in net asset category among its peers.
Acumen Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Acumen Pharmaceuticals from analyzing Acumen Pharmaceuticals' financial statements. These drivers represent accounts that assess Acumen Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Acumen Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 575.9M | 135.6M | 219.3M | 103.2M | 118.7M | 112.8M | |
| Enterprise Value | 532.1M | 13.4M | 89.3M | 97.3M | 111.9M | 106.3M |
Acumen Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Acumen Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Acumen Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acumen Pharmaceuticals' value.| Shares | Geode Capital Management, Llc | 2025-03-31 | 861.9 K | Jpmorgan Chase & Co | 2025-03-31 | 832.3 K | Hudson Bay Capital Management Lp | 2025-03-31 | 770 K | State Street Corp | 2025-03-31 | 521.2 K | Two Sigma Advisers, Llc | 2025-03-31 | 463.7 K | Northern Trust Corp | 2025-03-31 | 289.8 K | Ikarian Capital, Llc | 2025-03-31 | 265.8 K | Renaissance Technologies Corp | 2025-03-31 | 256.7 K | Two Sigma Investments Llc | 2025-03-31 | 232.3 K | Ra Capital Management, Llc | 2025-03-31 | 14.9 M | Sands Capital Ventures, Llc | 2025-03-31 | 3.4 M |
Acumen Fundamentals
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | (31.71 M) | ||||
| Shares Outstanding | 60.57 M | ||||
| Shares Owned By Insiders | 11.45 % | ||||
| Shares Owned By Institutions | 72.23 % | ||||
| Number Of Shares Shorted | 1.51 M | ||||
| Price To Book | 0.57 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | (106.61 M) | ||||
| EBITDA | (98.08 M) | ||||
| Net Income | (102.33 M) | ||||
| Cash And Equivalents | 189.91 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 29.7 M | ||||
| Current Ratio | 37.21 X | ||||
| Book Value Per Share | 2.57 X | ||||
| Cash Flow From Operations | (86.22 M) | ||||
| Short Ratio | 1.87 X | ||||
| Earnings Per Share | (1.80) X | ||||
| Price To Earnings To Growth | (0.23) X | ||||
| Target Price | 7.8 | ||||
| Number Of Employees | 61 | ||||
| Beta | 0.11 | ||||
| Market Capitalization | 95.1 M | ||||
| Total Asset | 238.99 M | ||||
| Retained Earnings | (325.13 M) | ||||
| Working Capital | 150.7 M | ||||
| Net Asset | 238.99 M |
About Acumen Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acumen Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acumen Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acumen Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.